Evofem Biosciences Inc. [NASDAQ: EVFM] stock went on a downward path that fall over -0.81% on Thursday, amounting to a one-week price decrease of less than -4.50%. The company report on June 2, 2022 that US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that the U.S. Food and Drug Administration (FDA) has formally extended the shelf life of Phexxi® (lactic acid, citric acid, potassium bitartrate) from three to four years.
“The FDA’s approval to extend Phexxi’s shelf life to four years speaks not only to the safety of our ingredients but also to the exceptional standards applied in the manufacturing of Phexxi,” said Saundra Pelletier, Chief Executive Officer at Evofem. “As we continue our long-term strategy to reduce operating expenses, this shelf life extension provides a significant and valuable operational efficiency, solidifying our ability to manage inventory within the growing US market and as we evaluate our strategic opportunities for the global licensing of Phexxi.”.
Over the last 12 months, EVFM stock dropped by -97.40%. The one-year Evofem Biosciences Inc. stock forecast points to a potential upside of 98.73. The average equity rating for EVFM stock is currently 2.20, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $5.02 million, with 163.14 million shares outstanding and 155.32 million shares in the current float. Compared to the average trading volume of 1.02M shares, EVFM stock reached a trading volume of 8855063 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Evofem Biosciences Inc. [EVFM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EVFM shares is $26.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EVFM stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on October 02, 2020, representing the official price target for Evofem Biosciences Inc. stock. Previously, the target price had yet another raise to $3, while Morgan Stanley analysts kept a Equal-Weight rating on EVFM stock.
The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.16, with the Price to Sales ratio for EVFM stock in the period of the last 12 months amounting to 0.44.
EVFM Stock Performance Analysis:
Evofem Biosciences Inc. [EVFM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.50. With this latest performance, EVFM shares dropped by -86.11% in over the last four-week period, additionally sinking by -94.52% over the last 6 months – not to mention a drop of -97.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 14.08, with the RSI for the last a single of trading hit 13.60, and the three-weeks RSI is set at 16.83 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 2.6376, while it was recorded at 0.3494 for the last single week of trading, and 6.9703 for the last 200 days.
Insight into Evofem Biosciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Evofem Biosciences Inc. [EVFM] shares currently have an operating margin of -2023.30 and a Gross Margin at +21.37. Evofem Biosciences Inc.’s Net Margin is presently recorded at -2488.99.
Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.10 and a Current Ratio set at 0.10.
Evofem Biosciences Inc. [EVFM] Insider Position Details
There are presently around $0 million, or 13.50% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: VANGUARD GROUP INC with ownership of 427,971, which is approximately -6.438% of the company’s market cap and around 1.30% of the total institutional ownership; BLACKROCK INC., holding 260,687 shares of the stock with an approximate value of $90000.0 in EVFM stocks shares; and MIRADOR CAPITAL PARTNERS LP, currently with $65000.0 in EVFM stock with ownership of nearly 3408.679% of the company’s market capitalization.
Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 25 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 253,777 shares. Additionally, 23 investors decreased positions by around 489,600 shares, while 25 investors held positions by with 590,914 shares. The mentioned changes placed institutional holdings at 1,334,291 shares, according to the latest SEC report filing. EVFM stock had 10 new institutional investments in for a total of 10,262 shares, while 6 institutional investors sold positions of 259,687 shares during the same period.